FIBROGEN, INC.

FGEN
Delayed Quote. Delayed  - 01/20 04:00:00 pm
44.65USD +1.43%

FIBROGEN INC : Entry into a Material Definitive Agreement (form 8-K)

11/12/2020 | 04:48pm

Item 1.01 Entry into a Material Definitive Agreement.

On November 9, 2020, FibroGen, Inc. ("FibroGen") entered into a Master Services Agreement (the "MSA") with Samsung Biologics Co., Ltd. ("Samsung"), pursuant to which Samsung will provide FibroGen with certain biologics manufacturing services in accordance with one or more product specific agreements.

The MSA shall remain in effect for so long as a product specific agreement is in effect. The MSA contains standard termination clauses for material breach and insolvency, as well as standard indemnification obligations of FibroGen and of Samsung.

In connection with the MSA, on November 9, 2020, FibroGen and Samsung entered into a product specific agreement (the "PSA") for the manufacturing and supply of pamrevlumab drug substance, for clinical and commercial use. The PSA contains product purchase and manufacturing commitments on the part of FibroGen and Samsung, respectively, over the next two years, invoiced on a per-batch basis, as well as technology transfer and other related services. The PSA contains customary limitations on liability, and performance of services thereunder is subject to the terms of the MSA.

The foregoing description of the MSA and PSA are not complete descriptions thereof, and are qualified in their entirety by reference to the full text of the MSA and PSA, which will be filed with the Securities and Exchange Commission as exhibits to FibroGen's Annual Report on Form 10-K for the year ending December 31, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

© Acquiremedia 2021
Copier lien
All news about FIBROGEN, INC.
01/08
12/22
12/22
12/21
12/21